Table 3.
Hazard of eGFR decline of 40% from baseline eGFR within 1 year from the onset of systemic therapy.
| Dependent: 40% eGFR decline within 1 year of systemic therapy | Total (n) | HR (CPH univariable) | HR (CPH multivariable) | HR (Competing risks multivariable) | |
|---|---|---|---|---|---|
| Age at treatment | Median (IQR) | 63.0 (55.0–71.0) | 1.01 (0.99v1.03, p = 0.379) | 1.01 (0.99–1.04, p = 0.228) | 1.01 (0.99–1.03, p = 0.380) |
| Nephrectomy prior to systemic therapy | Yes | 153 | - | - | - |
| No | 204 | 0.87 (0.56–1.34, p = 0.517) | 0.90 (0.57–1.43, p = 0.663) | 1.22 (0.71–2.12, p = 0.470) | |
| Sex | Male | 227 | - | - | - |
| Female | 130 | 0.97 (0.62–1.53, p = 0.896) | 0.99 (0.63–1.56, p = 0.966) | 0.91 (0.54–1.53, p = 0.720) | |
| Average eGFR < 60 prior to systemic therapy | Yes | 96 | - | - | - |
| No | 261 | 1.08 (0.66–1.77, p = 0.762) | 1.28 (0.75–2.16, p = 0.363) | 0.94 (0.54–1.63, p = 0.840) | |
| Diabetes | No | 307 | - | - | - |
| Yes | 50 | 1.77 (1.04–3.01, p = 0.037) | 1.76 (1.03–3.01, p = 0.040) | 2.01 (1.11–3.62, p = 0.021) | |
| Metastatic cancer | No | 238 | - | - | - |
| Yes | 119 | 0.70 (0.43–1.15, p = 0.158) | 0.72 (0.43–1.22, p = 0.225) | 0.87 (0.49–1.55, p = 0.640) |
This is demonstrated as univariable and multivariable cox proportional hazards (CPH) for developing this decline. Fine and Grey subdistribution hazards for developing this decline with a competing risk of death (competing risks multivariable). Multivariable adjustment for all the included covariates.